Current AD research focuses on understanding pathology by targeting several mechanisms, such as abnormal tau protein metabolism, -amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD (Tamagno et al., 2021)
As a ghrelin mimetic, ipamorelin binds to ghrelin receptors in the pituitary gland, prompting the body to release growth hormone, which encourages cell and tissue proliferation
This precision medicine approach may also guide dosage and timing, two factors previously identified as critical to therapeutic success (Santacroce et al., 2024)
Practical timeline expectations For researchers who decide to proceed with a combined protocol despite the unknown risks, realistic timeline expectations help set appropriate milestones for evaluation
Lab Testing: What Gets Measured and Why It Matters Lab work plays a real role in safe GLP-1 treatment